Orally active KDR tyrosine kinase inhibitor effective in spontaneously metastatic human tumor model Oct. 31, 2001
AACR-NCI-EORTC news: little severe toxicity seen in dose-escalating trial of IL-2 mutein Oct. 31, 2001
RSS